This Week in Biotech: Twitter Edition
As another week in biotech comes to a close, I've got a fresh batch of tweets that were entertaining and educational. As a reminder, if you've got a tweet you think is worthy of this weekly column, send me a link @BiologyFool.
The line between big pharma and big biotech is becoming increasingly blurry. Gilead Sciences , traditionally called a biotech even though most of its drugs are small molecules, went over the $100 million market cap threshold this month.
Gilead's recent success can be attributed to its diversification away from its HIV program. Those drugs are still providing a majority of the cash flow, but investors no longer have to worry about the eventual demise of the program to generic competition. Gilead can count on its hepatitis C and oncology programs to be the next big thing.
Gilead is the size of a pharma because it's looking more and more like one with every in-licensed drug, and positive clinical trial.
Biotech IPOs: The Exit Challenge As Lockups Expire [blog]. $10B in VC positions awaiting liquidity in '13 IPO Class. http://t.co/ZS70ZoOTtR— Bruce Booth (@LifeSciVC) October 31, 2013
Biotech IPOs have been on fire lately, but initial public offerings in this sector aren't exits for the venture capitalist that invested in the private companies. When they IPO, biotechs sell new shares to raise additional capital. Bruce estimates that VCs still own about 60% of the shares in the recent IPOs.
The big fear is that insiders will rush to the exit to get out after the lockup period ends to capitalize on their unrealized gains. Bruce offers a few ways start-ups can keep that from happening. If you're invested in a recent IPO, it's a must read. (And it's insightful, even if you're not.)
At the end of each month I get my report download stats from First-Call. PDLI-IR team downloaded the DEPO report 6 times in Sept / Oct.— Jason Napodano, CFA (@JNapodano) November 1, 2013
Smart investors get a variety of opinions when making investment decisions. Apparently, that goes for companies, as well.
Last month, PDL Biopharma paid Depomed $240 million in exchange for royalties Depomed receives from six different drugmakers. Clearly, that's only a good investment if PDL Biopharma can recoup its initial investment quickly. It makes sense to get independent opinions of Depomed's future royalty estimates from analysts like Jason. Apparently, it was a good reference if they downloaded it six times.
To the traders who are bailing on $VRTX: you want to invest in the co's that have the biggest impact on patients' lives. That's still them.— Brad Loncar (@bradloncar) November 1, 2013
Vertex Pharmaceuticals fell this week after announcing that sales of its hepatitis C drug Incivek are on a steep decline. Patients and their doctors are increasingly waiting for the next-generation drugs from Gilead Sciences and Johnson & Johnson that are on the horizon.
Of course, long-term investors were holding Vertex for its cystic fibrosis program rather than its prospects in hepatitis C. The decline might have been steeper than people would have expected, but Vertex's long-term prospects in cystic fibrosis haven't changed. Vertex's drug combinations have the potential to treat the underlying cause of the disease, while current treatments only treat the symptoms.
Brad's advice to look for companies that will have the biggest impact on patients is good strategy for biotech investors. I'd throw Sarepta Therapeutics out there as another example. Its revolutionary Duchenne muscular dystrophy drug, eteplirsen, treats a disease where patients currently have no options. In the short term, there's doubt over whether the FDA will approve eteplirsen based on the limited data. But over the longer term, it seems extremely likely that Sarepta Therapeutics can eventually get the drug approved after running a larger trial.
I think @BsiflingTrades might have the right idea with Sarepta:
Someone just wake me up in 2015 when this is all over and done with lol $SRPT— BsiflingTrades (@BsiflingTrades) October 30, 2013
Speaking of long-term investments
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!
The article This Week in Biotech: Twitter Edition originally appeared on Fool.com.Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Amazon.com, Apple, Facebook, Gilead Sciences, Google, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Amazon.com, Apple, Facebook, Google, and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.